Martin M.h. Prins

Martin M.h. Prins's AcademicInfluence.com Rankings

Martin M.h. Prins

Philosophy

#4762

World Rank

#7398

Historical Rank

Logic

#2154

World Rank

#3082

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Martin M.h. Prins's Degrees

PhD Medicine University of Amsterdam
Doctorate Medicine University of Amsterdam

Why Is Martin M.h. Prins Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Martin M.h. Prins's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Oral rivaroxaban for symptomatic venous thromboembolism. (2010) (2225)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. (2003) (2222)
The Long-Term Clinical Course of Acute Deep Venous Thrombosis (1996) (2040)
The diagnostic odds ratio: a single indicator of test performance. (2003) (1918)
Empirical evidence of design-related bias in studies of diagnostic tests. (1999) (1811)
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. (2004) (1730)
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. (2012) (1713)
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. (2002) (1681)
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. (2013) (1643)
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (1348)
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial (2007) (1159)
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. (1996) (1112)
Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. (2006) (1028)
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. (2005) (914)
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial (2006) (799)
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. (1997) (773)
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. (2000) (726)
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. (1992) (697)
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. (2003) (643)
An association between atherosclerosis and venous thrombosis. (2003) (625)
The effect of low molecular weight heparin on survival in patients with advanced malignancy. (2005) (593)
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. (2010) (576)
Safety of Low-Molecular-Weight Heparin in Pregnancy: A Systematic Review (1999) (549)
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies (2013) (534)
Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism (2002) (527)
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (2017) (521)
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. (2005) (475)
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints (1999) (447)
Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. (1995) (447)
Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. (2005) (430)
A Meta-analysis on the Efficacy of Preoperative Biliary Drainage for Tumors Causing Obstructive Jaundice (2002) (424)
Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. (1999) (418)
Below-Knee Elastic Compression Stockings To Prevent the Post-Thrombotic Syndrome (2004) (399)
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. (2006) (396)
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). (1997) (391)
Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis (2004) (354)
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: A randomized, controlled trial (2005) (342)
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. (2008) (336)
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial (2004) (326)
Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison (2000) (325)
Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. (2008) (324)
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. (2000) (313)
Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. (2013) (308)
Idraparinux versus standard therapy for venous thromboembolic disease. (2007) (292)
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial (2008) (289)
Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome (2005) (276)
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. (1999) (273)
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study (1999) (266)
Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. (2004) (265)
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study (2008) (258)
Left Bundle-Branch Block Induced by Transcatheter Aortic Valve Implantation Increases Risk of Death (2012) (257)
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. (2010) (250)
Single-Detector Helical Computed Tomography as the Primary Diagnostic Test in Suspected Pulmonary Embolism: A Multicenter Clinical Management Study of 510 Patients (2003) (249)
Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. (2000) (249)
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. (2014) (248)
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. (2009) (231)
Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. (2009) (227)
Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. (2007) (226)
Influence of smoking on incidence and prevalence of peripheral arterial disease. (2004) (222)
Frequency of Pregnancy-Related Venous Thromboembolism in Anticoagulant Factor-Deficient Women: Implications for Prophylaxis (1996) (217)
Diagnostic Strategies for Excluding Pulmonary Embolism in Clinical Outcome Studies (2003) (215)
Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? (2002) (213)
Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes (2011) (213)
The Incidence of Venous Thromboembolism in Family Members of Patients with Factor V Leiden Mutation and Venous Thrombosis (1998) (209)
Simplification of the diagnostic management of suspected deep vein thrombosis. (2002) (205)
A Prospective Study of Asymptomatic Carriers of the Factor V Leiden Mutation To Determine the Incidence of Venous Thromboembolism (2001) (199)
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. (2010) (198)
Low molecular weight heparin: a critical analysis of clinical trials. (1994) (194)
Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis (2006) (182)
The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. (2007) (182)
Smoking and the patency of lower extremity bypass grafts: a meta-analysis. (2005) (180)
Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope. (2016) (170)
Increased Risk for Fetal Loss in Carriers of the Factor V Leiden Mutation (1999) (164)
Undiagnosed malignancy in patients with deep vein thrombosis (1998) (163)
Secondary prophylaxis with warfarin for venous thromboembolism. (2003) (157)
The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study (2004) (156)
Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation (2008) (152)
Recurrence of venous thromboembolism in patients with familial thrombophilia. (1997) (152)
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. (2016) (151)
An evidence-based review of prognostic factors for glaucomatous visual field progression. (2013) (150)
Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. (2011) (145)
Is extensive screening for cancer in idiopathic venous thromboembolism warranted? (2011) (143)
Deep-vein thrombosis (1999) (142)
Physical Activity and Asthma: A Systematic Review and Meta-Analysis (2012) (141)
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose infractionated heparin for venous thromboembolism [Cochrane review] (2004) (140)
Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study (2012) (140)
A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. (1991) (137)
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis (2019) (136)
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. (2014) (135)
Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. (1989) (131)
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. (2019) (130)
Guidelines were developed for data collection from medical records for use in retrospective analyses. (2005) (129)
Angioplasty or bypass for superficial femoral artery disease? A randomised controlled trial. (2004) (128)
Diagnosis of arterial disease of the lower extremities with duplex ultrasonography (1996) (125)
Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. (2004) (124)
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. (2014) (124)
Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. (2005) (123)
The 20210 G → A mutation in the 3′‐untranslated region of the prothrombin gene and the risk for arterial thrombotic disease (1999) (120)
Safety of Treatment with Oral Anticoagulants in the Elderly (1999) (120)
Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A (2010) (118)
Extended prophylaxis of venous thromboembolism with idraparinux. (2007) (116)
Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes (2010) (116)
Diagnosing acute pulmonary embolism: effect of chronic obstructive pulmonary disease on the performance of D-dimer testing, ventilation/perfusion scintigraphy, spiral computed tomographic angiography, and conventional angiography. ANTELOPE Study Group. Advances in New Technologies Evaluating the Loc (2000) (115)
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. (2008) (114)
Management studies using a combination of D‐dimer test result and clinical probability to rule out venous thromboembolism: a systematic review (2005) (112)
Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. (2004) (112)
Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. (2012) (111)
Venous thromboembolism and occult malignancy. (2001) (108)
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery (2007) (105)
Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. (2003) (104)
Non-pharmaceutical measures for prevention of post-thrombotic syndrome. (2003) (103)
Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. (2010) (103)
Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity: A Phase II Evaluation (2000) (101)
Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. (2003) (101)
Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials (2009) (98)
Carotid Stiffness in Young Adults: A Life-Course Analysis of its Early Determinants The Amsterdam Growth and Health Longitudinal Study (2012) (97)
Accuracy of single‐detector spiral CT in the diagnosis of pulmonary embolism: a prospective multicenter cohort study of consecutive patients with abnormal perfusion scintigraphy (2005) (97)
Reliability of treadmill testing in peripheral arterial disease: a meta-regression analysis. (2009) (95)
The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. (2003) (95)
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism (2014) (95)
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program (2015) (94)
The walking impairment questionnaire: an effective tool to assess the effect of treatment in patients with intermittent claudication. (2009) (93)
Microcirculatory investigations to determine the effect of spinal cord stimulation for critical leg ischemia: the Dutch multicenter randomized controlled trial. (1999) (93)
Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. (1999) (93)
Low-molecular weight heparin in the treatment of patients with venous thromboembolism: the Columbus Investigators (1997) (92)
Definition of the post-thrombotic syndrome, differences between existing classifications. (2005) (91)
Lifetime Vigorous But Not Light-To-Moderate Habitual Physical Activity Impacts Favorably on Carotid Stiffness in Young Adults: The Amsterdam Growth and Health Longitudinal Study (2010) (89)
Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory (2008) (89)
A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. (1998) (89)
A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. (2009) (86)
Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. (2002) (85)
Endovascular aneurysm repair is superior to open surgery for ruptured abdominal aortic aneurysms in EVAR-suitable patients. (2010) (85)
The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis. (2002) (85)
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis (2013) (84)
Edoxaban for the long‐term treatment of venous thromboembolism: rationale and design of the Hokusai‐venous thromboembolism study – methodological implications for clinical trials (2013) (81)
Safely Ruling Out Deep Venous Thrombosis in Primary Care (2009) (81)
Benchmark for Time in Therapeutic Range in Venous Thromboembolism: A Systematic Review and Meta-Analysis (2012) (81)
Beneficial effects of biventricular pacing in chronically right ventricular paced patients with mild cardiomyopathy. (2010) (80)
Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences (2004) (79)
Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review (2004) (78)
[From the Cochrane Library: increased walking distance through supervised exercise therapy in patients with intermittent claudication]. (2008) (78)
Multimodality Imaging of Carotid Artery Plaques: 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography, Computed Tomography, and Magnetic Resonance Imaging (2009) (78)
Low body mass index, anaemia and poor perinatal outcome in a rural hospital in eastern Sudan. (2007) (77)
Does fast-track treatment lead to a decrease of intensive care unit and hospital length of stay in coronary artery bypass patients? A meta-regression of randomized clinical trials* (2006) (76)
Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. (2011) (76)
All that glisters is not gold: a comparison of electronic monitoring versus filled prescriptions – an observational study (2006) (75)
The Lachman test is the most sensitive and the pivot shift the most specific test for the diagnosis of ACL rupture. (2006) (75)
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. (2015) (75)
The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation (2015) (73)
Thrombin generation in patients after acute deep-vein thrombosis (2008) (73)
A critical review of the relationship between impaired fibrinolysis and myocardial infarction. (1991) (73)
Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. (2010) (72)
A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. (2006) (72)
Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. (1999) (72)
Contrast-enhanced ultrasound versus computed tomographic angiography for surveillance of endovascular abdominal aortic aneurysm repair. (2010) (71)
Once versus twice daily LMWH for the initial treatment of venous thromboembolism. (2002) (71)
Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. (2011) (70)
Supervised exercise therapy for intermittent claudication in a community-based setting is as effective as clinic-based. (2007) (69)
Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. (2018) (68)
Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study (2009) (68)
Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. (2002) (68)
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutationRisk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis (2000) (68)
Electronic monitoring of adherence as a tool to improve blood pressure control. A randomized controlled trial. (2007) (67)
MRI of carotid atherosclerosis to identify TIA and stroke patients who are at risk of a recurrence (2013) (67)
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis (2011) (67)
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. (2000) (66)
Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. (2012) (65)
Decision analysis for cancer screening in idiopathic venous thromboembolism (2005) (65)
Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygotes for lipoprotein lipase deficiency. (1996) (65)
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. (2015) (64)
A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. (2009) (64)
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. (2010) (63)
Risk of recurrent venous thromboembolism according to baseline risk factor profiles. (2018) (63)
Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. (1998) (62)
The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. (1998) (62)
Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force. (2006) (62)
Treatment of venous thromboembolism with rivaroxaban in relation to body weight (2016) (62)
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial (2012) (60)
Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors (2007) (60)
Safely Ruling Out Deep Venous Thrombosis in Primary Care (2009) (59)
Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis. (2000) (59)
Determinants of poor adherence in hypertensive patients: development and validation of the "Maastricht Utrecht Adherence in Hypertension (MUAH)-questionnaire". (2006) (59)
Triage of patients for short term observation after elective coronary angioplasty (2000) (58)
Additional supervised exercise therapy after a percutaneous vascular intervention for peripheral arterial disease: a randomized clinical trial. (2011) (58)
Validation of the Dutch version of the Walking Impairment Questionnaire. (2009) (57)
Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the 'Perception of Anticoagulant Treatment Questionnaire' (PACT-Q©) (2009) (56)
Cost-effectiveness of exercise therapy in patients with intermittent claudication: supervised exercise therapy versus a 'go home and walk' advice. (2011) (56)
Compression therapy for prevention of post-thrombotic syndrome. (2017) (56)
Compression therapy for treating stage I and II (Widmer) post-thrombotic syndrome. (2003) (55)
Adherence to a Mediterranean dietary pattern in early life is associated with lower arterial stiffness in adulthood: the Amsterdam Growth and Health Longitudinal Study (2013) (55)
Individually tailored duration of elastic compression therapy in relation to incidence of the postthrombotic syndrome. (2010) (55)
Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment (2014) (55)
The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders (2002) (54)
Ankle brachial index measurement in primary care: are we doing it right? (2009) (53)
The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients (2008) (53)
Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. (1991) (53)
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism (2015) (53)
Symptomatic Patients With Mild and Moderate Carotid Stenosis: Plaque Features at MRI and Association With Cardiovascular Risk Factors and Statin Use (2010) (53)
Does the Pulmonary Embolism Severity Index accurately identify low risk patients eligible for outpatient treatment? (2012) (52)
Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis (2016) (50)
Potential of Integrated [18F] Fluorodeoxyglucose Positron-Emission Tomography/CT in Identifying Vulnerable Carotid Plaques (2011) (49)
The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects (2007) (48)
For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? (2000) (47)
Lower lifetime dietary fiber intake is associated with carotid artery stiffness: the Amsterdam Growth and Health Longitudinal Study. (2012) (47)
Circulating Intestinal Fatty Acid-Binding Protein as an Early Marker of Intestinal Necrosis After Aortic Surgery: A Prospective Observational Cohort Study (2012) (47)
Comparing the Diagnostic Performance of 2 Clinical Decision Rules to Rule Out Deep Vein Thrombosis in Primary Care Patients (2011) (46)
Functional claudication distance: a reliable and valid measurement to assess functional limitation in patients with intermittent claudication (2009) (46)
A clinical prediction model for the presence of peripheral arterial disease — the benefit of screening individuals before initiation of measurement of the ankle—brachial index: an observational study (2007) (46)
The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. (2010) (44)
Risk stratification of patients with pulmonary embolism based on pulse rate and D-dimer concentration (2009) (43)
Idiopathic deep venous thrombosis. Is a search for malignant disease justified? (1994) (43)
Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. (2016) (42)
ABO blood group system and placental malaria in an area of unstable malaria transmission in eastern Sudan (2007) (40)
Low birth weight, preterm birth and short interpregnancy interval in Sudan (2009) (40)
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. (2019) (39)
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism (2005) (39)
Low-molecular Weight Heparins in Venous and Arterial Thrombotic Disease (1999) (39)
Supervised exercise therapy for intermittent claudication in daily practice. (2009) (39)
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation (2019) (38)
Ginkgo biloba for intermittent claudication. (2013) (38)
Optimizing supervised exercise therapy for patients with intermittent claudication. (2010) (36)
The scale of the problem (2009) (36)
Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels (2008) (35)
Diagnostic strategies for the management of patients with clinically suspected deep‐vein thrombosis (1997) (35)
Habitual physical activity and peripheral arterial compliance in young adults: the Amsterdam growth and health longitudinal study. (2011) (34)
Which Is the Outcome of the Post-thrombotic Syndrome? (1999) (33)
Low-Molecular-Weight Heparins: Are They Interchangeable? (2000) (33)
Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c (2007) (33)
Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect: a retrospective analysis (2001) (33)
Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the EINSTEIN PE Study (2015) (32)
The Impact of a Nationwide Introduction of New Drugs and a Treatment Protocol for Glaucoma on the Number of Glaucoma Surgeries (2005) (32)
Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies (2013) (32)
Technegas Versus 81mKr Ventilation-Perfusion Scintigraphy: A Comparative Study in Patients with Suspected Acute Pulmonary Embolism (2001) (32)
Single intravenous administration of TB‐402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose‐escalating, randomized, controlled trial (2011) (32)
Longitudinal MRI Study on the Natural History of Carotid Artery Plaques in Symptomatic Patients (2012) (31)
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. (2004) (31)
Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. (2007) (31)
Arterial wall thickness and the risk of recurrent ischemic events in carriers of the prothrombin G20210A mutation with clinical manifestations of atherosclerosis. (2002) (30)
Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. (2002) (30)
Simple Prepregnant Prediction Rule for Recurrent Early-onset Hypertensive Disease in Pregnancy (2009) (30)
A review on the design and reporting of studies on drug-gene interaction. (2005) (30)
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study (2018) (30)
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. (2006) (30)
Symptomatic peripheral arterial disease: the value of a validated questionnaire and a clinical decision rule. (2006) (30)
Integrated specialized atrial fibrillation clinics reduce all-cause mortality: post hoc analysis of a randomized clinical trial. (2019) (29)
Quantifying the effect of intraocular pressure reduction on the occurrence of glaucoma (2010) (29)
Comparison of observer variability and accuracy of different criteria for lung scan interpretation. (2003) (29)
Risk Assessment and Prophylaxis of Venous Thromboembolism in Non-Surgical Patients: Cancer as a Risk Factor (2000) (29)
Familial Thrombophilia: A Review Analysis (1996) (29)
Plasma levels of matrix metalloproteinase-9: a possible diagnostic marker of successful endovascular aneurysm repair. (2012) (28)
EVAR suitability is not a predictor for early and midterm mortality after open ruptured AAA repair. (2011) (28)
Clinical and echocardiographic correlates of intra-atrial conduction delay. (2011) (28)
Peripheral arterial disease: public and patient awareness in The Netherlands. (2004) (27)
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). (2020) (27)
Prediction Tests for Recurrent Hypertensive Disease in Pregnancy, A Systematic Review (2010) (27)
Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism (2013) (26)
YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study. (2005) (26)
The association between study characteristics and outcome in the relation between job stress and cardiovascular disease - a multilevel meta-regression analysis. (2012) (26)
Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban‐treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding (2016) (26)
A Comparison of 3 Valuation Methods for Temporary Health States in Patients Treated with Oral Anticoagulants (2004) (26)
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. (2016) (25)
Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist (2008) (24)
Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin (2008) (24)
Clinically suspected acute recurrent pulmonary embolism: A diagnostic challenge (2007) (24)
Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials. (2007) (24)
How to use a gestalt interpretation for ventilation-perfusion lung scintigraphy. (2002) (24)
Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients (2012) (23)
Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study (2010) (23)
Double‐blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants (2008) (23)
Carotid Plaques in Transient Ischemic Attack and Stroke Patients: One-Year Follow-up Study by Magnetic Resonance Imaging (2010) (23)
The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial (2014) (22)
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: A subgroup analysis of the Van Gogh DVT trial (2010) (22)
Troponin T measurements by high-sensitivity vs conventional assays for risk stratification in acute dyspnea. (2012) (22)
Self-reported time spent watching television is associated with arterial stiffness in young adults: the Amsterdam Growth and Health Longitudinal Study (2013) (21)
Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study (1998) (21)
Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program (2015) (21)
Continuing smoking between adolescence and young adulthood is associated with higher arterial stiffness in young adults: the Northern Ireland Young Hearts Project (2011) (21)
Compression therapy for treating post-thrombotic syndrome. (2019) (20)
Limitations of screening for occult cancer in patients with idiopathic venous thromboembolism. (2012) (20)
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). (2020) (20)
Higher plasma soluble receptor for advanced glycation endproducts (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-yr follow-up study (2010) (20)
The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolism (2003) (19)
Feasibility of TEE-guided stroke risk assessment in atrial fibrillation—background, aims, design and baseline data of the TIARA pilot study (2011) (19)
Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy (2014) (19)
Predictors of walking distance after supervised exercise therapy in patients with intermittent claudication. (2009) (19)
Patient-Reported Treatment Satisfaction with Oral Rivaroxaban Versus Standard Therapy in the Treatment of Acute Symptomatic Pulmonary Embolism (2012) (18)
Methodologic ramifications of paying attention to sex and gender differences in clinical research. (2007) (18)
Applicability of the ankle-brachial-index measurement as screening device for high cardiovascular risk: an observational study (2012) (18)
Predicting mortality in damage control surgery for major abdominal trauma. (2010) (18)
Should Patients with Venous Thromboembolism and Cancer Be Treated Differently? (1999) (18)
Out-of-Hospital Treatment of Venous Thrombosis: Socioeconomic Aspects and Patients’ Quality of Life (1998) (17)
Pocket Doppler and vascular laboratory equipment yield comparable results for ankle brachial index measurement (2008) (17)
A Randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). (2002) (17)
Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia (2002) (17)
Adverse event detection by medical record review is reproducible, but the assessment of their preventability is not (2018) (17)
Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia (2001) (16)
Single nucleotide polymorphisms in inflammation-related genes are associated with venous thromboembolism. (2010) (16)
Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the EINSTEIN DVT and EINSTEIN PE Studies (2015) (16)
Treatment for intermittent claudication and the effects on walking distance and quality of life (2012) (16)
Thromboprophylaxis in Non-Surgical Patients:Who, When and How? (1998) (15)
Post-thrombotic syndrome and the risk of subsequent recurrent thromboembolism. (2016) (15)
Severity of venous insufficiency is related to the density of microvascular deposition of PAI-1, uPA and von Willebrand factor. (2004) (15)
Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction (2018) (15)
Risk of Recurrent Venous Thomboembolism – Expanding the Frontier (2002) (15)
The evidence base to select a method for assessing glaucomatous visual field progression (2012) (15)
Unselected women with elevated levels of factor VIII:C or homocysteine are not at increased risk for obstetric complications (2004) (15)
Technegas versus (81m)Kr ventilation-perfusion scintigraphy: a comparative study in patients with suspected acute pulmonary embolism. (2001) (15)
Study DVT Dose-Ranging - symptomatic deep vein thrombosis: the Einstein factor Xa inhibitor rivaroxaban in the treatment of patients with acute A dose-ranging study evaluating once-daily oral administration of the (2013) (15)
Protein S type III deficiency is no risk factor for venous and arterial thromboembolism in 168 thrombophilic families: a retrospective study (2005) (15)
Ginkgo biloba for intermittent claudication. (2009) (14)
Thrombosis and cancer: a short history of Trousseau's syndrome [ch. 1] (2004) (14)
Hyperhomocysteinemia is not a risk factor for venous and arterial thrombosis, and is associated with elevated factor VIII levels. (2008) (14)
Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. (2012) (14)
The application of a Dutch consensus diagnostic strategy for pulmonary embolism in clinical practice. (2001) (14)
Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study (2014) (13)
Evaluation of a non-invasive bladder volume measurement in children (2008) (13)
Combined training of GPs and practice-assistants on peripheral arterial disease: positive effects after six months. (2005) (13)
The potential role of positron emission tomography in the detection of occult cancer in 25 patients with venous thromboembolism. (2008) (13)
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. (2017) (13)
Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study. (2009) (13)
Statins Do Not Reduce Atrial Fibrillation After Cardiac Valvular Surgery: A Single Centre Observational Study (2010) (13)
Predicting intraocular pressure change before initiating therapy: timolol versus latanoprost (2008) (12)
Physical activity and asthma development in childhood: Prospective birth cohort study (2019) (12)
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3) (2013) (12)
Videodensitometric quantitative angiography after coronary balloon angioplasty, compared to edge-detection quantitative angiography and intracoronary ultrasound imaging. (2000) (12)
Risk of cardiovascular disease in double heterozygous carriers and homozygous carriers of F5 R506Q (factor V Leiden) and F2 (prothrombin) G20210A: a retrospective family cohort study (2011) (11)
Effect of supervised exercise therapy for intermittent claudication in patients with diabetes mellitus. (2012) (11)
Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism (2012) (11)
Out of hospital anticoagulant therapy in patients with acute pulmonary embolism is frequently practised but not perfect. (2010) (10)
Prediction of Glaucomatous Visual Field Progression Using Baseline Clinical Data (2016) (10)
Changes in glaucoma treatment and achieved IOP after introduction of new glaucoma medication (2006) (10)
Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen versus LMWH-VKA Standard of Care (2012) (10)
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. (2018) (10)
Acute cardioversion vs a wait‐and‐see approach for recent‐onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial (2017) (10)
Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement. (2007) (10)
A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210 A mutation (2006) (10)
Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improve survival in patients with non-metastatic malignancy and venous thromboembolism (VTE) (2003) (9)
Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement (2013) (9)
The prospective relationship between work stressors and cardiovascular disease, using a comprehensive work stressor measure for exposure assessment (2013) (9)
Common alternative diagnoses in general practice when deep venous thrombosis is excluded. (2012) (9)
Safety of Outpatient Treatment In Acute Pulmonary Embolism. (2010) (9)
Additional Efficacy of Milligram-Equivalent Doses of Atorvastatin over Simvastatin (2000) (9)
Natural course of the subsequent pregnancy after a single loss in women with and without the factor V Leiden or prothrombin 20210A mutations. (2006) (9)
The ability of triggers to retrospectively predict potentially preventable adverse events in a sample of deceased patients (2017) (9)
Residual vein thrombosis and the risk of subsequent serious complications. (2015) (9)
The impact of a male or female thrombotic family history on contraceptive counseling: a cohort study (2016) (9)
Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost‐effectiveness analysis (2012) (8)
Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. (2000) (8)
Venous thromboembolism and occult malignancy: an historical perspective. (2001) (8)
Risk factors of arterial cardiovascular complications in patients with prior venous thromboembolism. (2011) (8)
No effect of rosuvastatin on left ventricular hypertrophy in patients with hypertension: a prospective randomised open-label study with blinded endpoint assessment. (2010) (8)
The influence of the assessment method on the incidence of visual field progression in glaucoma: a network meta‐analysis (2012) (8)
fixed-dose rivaroxaban is not associated with increased recurrent venous thromboembolism or major bleeding in patients with a high or low body weight : As099 (2015) (8)
Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer. (2016) (7)
Major orthopaedic surgery and post-discharge DVT (1996) (7)
Which heparin for proximal deep-vein thrombosis? (1992) (7)
Alternative diagnoses in patients in whom the GP considered the diagnosis of pulmonary embolism. (2014) (7)
Corrigendum to: ‘Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation’ [Eur Heart J 2012; 33:2692–2699, doi:10.1093/eurheartj/ehs071] (2013) (7)
Quality of life and the duration of treatment with vitamin K antagonists in patients with deep venous thrombosis (2003) (7)
LEVELS OF FACTOR VIII (FVIII), D-DIMER AND THROMBIN GENERATION (TG) IN PATIENTS AFTER ACUTE DEEP VEIN THROMBOSIS (DVT) (2007) (7)
Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group. (1998) (6)
Oral Rivaroxaban for Pulmonary Embolism REPLY (2012) (6)
A Systematic Review of Methods for Medical Record Analysis to Detect Adverse Events in Hospitalized Patients (2020) (6)
Contribution of age and intimal lesion morphology to coronary artery wall mechanics in coronary artery disease. (1995) (6)
Optimisation of the diagnostic strategy for suspected deep-vein thrombosis in primary care (2010) (6)
Elastic compression stockings for prevention of the post-thrombotic syndrome in patients with and without residual vein thrombosis and/or popliteal valve reflux. (2021) (6)
Does Low-Molecular-Weight Heparin Reduce the Costs of Venous Thromboembolism Treatment? (2000) (6)
Blood Coagulation and Cancer: Thrombosis and Survival, Clinical Relevance and Impact (2007) (6)
Excluding pulmonary embolism without imaging tests – Can our diagnostic algorithm be optimized? (2008) (6)
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial (2022) (6)
DEEP VENOUS THROMBOSIS PR0FYLAXIS WITH A LMW HEPARIN (KABI 2165) IN STROKE PATIENTS (1987) (5)
Peripheral Arterial Disease: The Gap Between Common Practice and the Dutch College of General Practitioners Guideline (2004) (5)
Low absolute risk of venous and arterial thrombosis in hyperhomocysteinaemia – A prospective family cohort study in asymptomatic subjects (2008) (5)
Low molecular weight heparins in cancer. Management and prevention of venous thromboembolism in patients with malignancies. (2008) (5)
Symptomatic abdominal aortic aneurysm repair: to wait or not to wait. (2016) (5)
Postintervention duration of anticoagulation in venous surgery (2013) (5)
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. (2014) (5)
Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis. (2018) (5)
Which Factors Are Associated with the Application of Reperfusion Therapy in ST-Elevation Acute Coronary Syndromes? (2006) (5)
Below-knee elastic compression stockings for prevention of the post-thrombotic syndrome in patients with proximal-vein thrombosis: a prospective controlled randomized study (2003) (5)
Predicting Recurrent Venous Thromboembolism in Patients With Deep-Vein Thrombosis: Development and Internal Validation of a Potential New Prediction Model (Continu-8) (2021) (5)
Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism (2022) (4)
Availability of diagnostic facilities in the Netherlands for patients with suspected pulmonary embolism. ANTELOPE Study Group. Advances in New Technologies Evaluating the Localisation of Pulmonary Embolism. (2000) (4)
Health‐care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN‐CHOICE Trial Population (2018) (4)
Secondary prophylaxis decision‐making in venous thromboembolism: interviews on clinical practice in thirteen countries (2017) (4)
Acute pulmonary embolism: impact of selection bias in prospective diagnostic studies. ANTELOPE Study Group. Advances in New Technologies Evaluating the Localization of Pulmonary Embolism. (2001) (4)
Oral contraceptives and inherited thrombophilia: a gene-environment interaction with a risk of venous thrombosis? (2003) (4)
The diagnostic performance of renal function-adjusted D-dimer testing in individuals suspected of having venous thromboembolism (2019) (4)
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. (2018) (4)
A number needed to screen and cost-effectiveness analysis of the SOMIT-data. (2001) (4)
Determinants of treatment duration in the prevention of recurrent venous thromboembolism: a protocol for a balanced vignette experiment (2017) (4)
Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. (2003) (4)
High factor VIII plasma levels as a risk factor for venous thrombosis: no evidence of inheritance from a family cohort study. (2004) (4)
Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism (2018) (3)
Pulmonary embolism as a first clinical sign of occult malignancy: A prospective follow-up study (2006) (3)
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. (2003) (3)
Fibrin D-dimer measurement in suspected pulmonary embolism. (2001) (3)
Extended Treatment of Venous Thromboembolism. (2017) (3)
Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin (2021) (3)
Randomised Controlled Trial of Rivaroxaban Compared to Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children (2019) (3)
From the Cochrane library: Ginkgo biloba for intermittent claudication. (2010) (3)
The effect of Fiberform®, a low‐phytate wheat fibre, on plasma lipids and blood pressure of women with familial hypercholesterolaemia (1994) (3)
Out of Hospital Treatment of Acute Pulmonary Embolism in Patients with a Low NT-ProBNP Level (2009) (3)
The incindence of venous thromboembolism in relatives of patients with the prothrombin 20210A mutation (1999) (3)
Anticoagulant Treatment in Patients with Cancer and Venous Thrombosis Recurrent Venous Thromboembolism and Bleeding Complications During (2013) (3)
Technegas Versus 81 mKr Ventilation – Perfusion Scintigraphy : A Comparative Study in Patients with Suspected Acute Pulmonary Embolism (2001) (3)
The impact of personal attributes on the association between cumulative exposure to work stressors and cardiovascular disease. (2013) (2)
Recurrent thromboembolism after treatment with vitamin K antagonists. (2003) (2)
Greater late lumen loss after successful coronary balloon angioplasty in the proximal left anterior descending coronary artery is not explained by extent of vessel wall damage or plaque burden. (2000) (2)
Appropriate level and length of postthrombotic warfarin treatment: an evaluation of recent developments (2004) (2)
Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’ (2016) (2)
The Clinical Impact of 2 Different Strategies for Initiating Therapy in Patients With Ocular Hypertension (2011) (2)
Determinants of severe post-thrombotic syndrome: The role of thrombus location. (2019) (2)
Single intravenous administration of TB-402 for the prophylaxis of VTE after total knee replacement surgery (2010) (2)
Limited external reproducibility restricts the use of medical record review for benchmarking (2019) (2)
Low-molecular-weight heparin and the survival of patients with advanced malignancy. (2004) (2)
Comparing oral rivaroxaban versus standard treatment in the treatment of symptomatic deep vein thrombosis: a patient-reported treatment satisfaction study (2012) (2)
Arteriall wall thickness and the risk of recurrent ischemic events in carriers off the prothrombin G20210A mutation with clinical manifestations of atherosclerosis s (2007) (2)
Inter-observer variation in reading ambulant venous pressure from invasive venous pressure curves: The need for clear guidelines (2005) (2)
Once versus twice daily LMWH for the initial treatment of venous thromboembolism. (2003) (2)
Pain-related comorbidity in depression: the association with 5-HTTLPR and STin2 (2006) (2)
Residual venous thrombosis and recurrent thromboembolism. Authors' reply (2003) (2)
The risk of recurrent venous thromboembolism and major bleeding in fragile patients with deep vein thrombosis (2011) (2)
Risk Factors for Thrombosis and Bleedings Prevention of Arterial and Venous Thrombosis Treatment of VTE and Adverse Reactions (1999) (1)
PCV50 COST-EFFECTIVENESS OF RULING OUT DEEPVENOUS THROMBOSIS IN PRIMARY CARE VERSUS CARE AS USUAL (2008) (1)
Venous thrombotic burden and the risk of subsequent overt cancer (2015) (1)
Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study (2019) (1)
Different Approaches to Estimate Exposure to Work Stressors, Using Repeated Measurements, and the Association With Cardiovascular Disease (2013) (1)
A blinded multicenter dose escalation phase IIa study of the factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in patients undergoing elective percutaneous coronary intervention (2002) (1)
AbstractRivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (2017) (1)
When do we need what evidence? (2003) (1)
Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. (2003) (1)
Prevalence of pulmonary embolism among patients with recent onset of dyspnea on exertion. A cross-sectional study. (2023) (1)
Pulmonary Embolism in Patients Hospitalized for Syncope. (2017) (1)
Thrombolytic Therapy ACCP Conference on Antithrombotic and Thromboembolic Disease : The Seventh Antithrombotic Therapy for Venous (2004) (1)
HYPERHOMOCYSTEINEMIA IS NOT A RISK FACTOR FOR VENOUS AND ARTERIAL THROMBOSIS, BUT AN EPIPHENOMENON: RESULTS FROM A LARGE RETROSPECTIVE FAMILY COHORT STUDY (2007) (1)
Greater central-to-peripheral pulse pressure amplification in diabetes and obesity: the relative mediating role of arterial stiffness, heart rate and wave reflection: The CODAM study (2014) (1)
Higher plasma advanced glycation endproducts levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study (2010) (1)
High Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels May Protect against Recurrent Fetal Loss (2008) (1)
[No indication for thrombophilia screening in patients with idiopathic venous thromboembolism and their relatives]. (2001) (1)
Prevention of early occlusion in symptomatic PAOD patients undergoing peripheral catheter intervention (2000) (1)
Does the risk of venous thromboembolism (VTE) in first degree family members of patients with VTE and the FV: Q(506) mutation justify family screening? (1997) (1)
Influence of concomitant thrombophilic defects on the risk of recurrent venous thromboembolism in carriers of factor V Leiden (1999) (1)
UvA-DARE ( Digital Academic Repository ) Secondary prophylaxis with warfarin for venous thromboembolism (2003) (0)
Elevated levels of FVIII (2005) (0)
Prevention of venous insufficiency in a standing workers population (2007) (0)
Aetiology and treatment of venous thromboembolism (2007) (0)
Forthcoming articles in the august issue (2005) (0)
proximal-venous thrombosis : a randomized trial prevention of the postthrombotic syndrome in patients with Thigh-length versus below-knee compression elastic stockings for (2012) (0)
Ultrasonography to Guide Duration of Anticoagulation in DVT (2009) (0)
Abstract 6137: Atrial Tissue Doppler Imaging For Prediction Of New-Onset Atrial Fibrillation (2008) (0)
Thrombophilia and Cardiovascular Risk Factors On the Absolute Risk of First and Recurrent Venous Thrombosis. Results From a Retrospective Family Cohort Study Involving 2097 Relatives. (2009) (0)
P11.06: FIBRONECTIN, BUT NOT LAMININ CONTENT IS INCREASED IN THE TUNICA MEDIA OF SUBCUTANEOUS SMALL RESISTANCE ARTERIES OF PATIENTS WITH ESSENTIAL HYPERTENSION (0)
81mKr Ventilation–Perfusion Scintigraphy: A Comparative Study in Patients with Suspected Acute Pulmonary Embolism (2001) (0)
Therapy of acute deep vein thrombosis and prevention of the post-thrombotic syndrome (2003) (0)
Clinical Course of Deep Venous Thrombosis (1997) (0)
Increase in the levels of matrix metalloproteinases 3 and 9 is associated with increase in pulse pressure and incident hypertension: 7-year longitudinal study (2013) (0)
P11.02: BRAIN WHITE MATTER LESIONS AND ARTERIAL WALL PARAMETERS IN MIGRAINE PATIENTS (0)
Detecting adverse events in clinical care using natural language processing (2019) (0)
Thromboprophylaxis in Pregnancy, Orthopaedic Surgery Patients and in Long-Term Strategies (1998) (0)
Life-course habitual physical activity and its impact on arterial stiffness: The Amsterdam Growth and Health Longitudinal Study (AGAHLS) (2008) (0)
The prothrombin 20210A mutation additionally increases the risk of venous thrombosis in carriers of factor V Leiden (1999) (0)
The risk of venous thromboembolism (VTE) in first degree family members of patients with VTE and the FV : Q(504) mutation. (1996) (0)
carriers of the prothrombin 20210A mutation thromboembolism and arterial cardiovascular disease in asymptomatic A prospective cohort study on the absolute incidence of venous (2010) (0)
2479 relatives absolute thrombotic risk for currently known thrombophilic defects in thrombosis: results from a retrospective family cohort study on Selective testing for thrombophilia in patients with first venous (2010) (0)
Statin Use Was Associated With a Non-Significant Reduction In The Observed Incidence Of Recurrent VTE In Einstein-DVT and Einstein-PE (2013) (0)
IMPACT OF CHANGES IN SMOKING BEHAVIOUR BETWEEN ADOLESCENCE AND YOUNG ADULTHOOD ON ARTERIAL STIFFNESS IN YOUNG ADULTS. THE NORTHERN IRELAND YOUNG HEARTS PROJECT (2009) (0)
Deep-vein thrombosis. (1999) (0)
Increased risk for venous thromboembolism and myocardial infarction in family members of patients with prothrombin 20210 A mutation (2003) (0)
Poster abstractB-mode ultrasound measurements show increased intima-media thickness of the combined far walls of the common carotid and carotid bulb in children heterozygous for familial hypercholesterolemia (1994) (0)
Mo-P1:127 Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis (2006) (0)
The performance of diagnostic tests for acute pulmonary embolism in patients with COPD (2001) (0)
CLINICAL COURSE OF DEEP VENOUS THROMBOSIS. AUTHORS' REPLY (1997) (0)
Genetic susceptibility to pre-eclampsia (1997) (0)
Television Time is Adversely Associated with Arterial Stiffness in Young Adults: The Amsterdam Growth and Health Longitudinal Study (2010) (0)
O18 High thrombin activatable fibrinolysis inhibitor (TAFI) levels may protect against recurrent early fetal loss (2009) (0)
Selective serotonin reuptake inhibitors in depression: the influence of 5-HTTLPR and STin2 on treatment effect (2006) (0)
Lifetime adherence to a Mediterranean diet (MD) pattern is associated with lower carotid stiffness in young adults: The Amsterdam growth and health longitudinal study (2011) (0)
Intermittent Claudication Revisited: The Value of Medical Therapy (1999) (0)
Associations of visceral vs. subcutaneous abdominal fat with central vs. peripheral arterial stiffness and the mediating role of low-grade inflammation herein (2014) (0)
Safety and e ﬃ cacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT) the EINSTEIN-Jr Cerebral trial (2020) (0)
UvA-DARE ( Digital Academic Repository ) Heparins , cancer and thrombosis : clinical and experimental studies (2009) (0)
Cost-effectivenes ss of noninvasiv e diagnosti c strategie ss in pulmonar y embolism (2007) (0)
Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr (2022) (0)
Longitudinal development of systolic blood pressure from adolescence to adulthood: Impact on carotid IMT (2008) (0)
Benefit of Fondaparinux in Medical Patients: A Subgroup Analysis. (2004) (0)
Life-course of mean arterial pressure and its impact on arterial stiffness: The Amsterdam Growth and Health Longitudinal Study (AGAHLS) (2008) (0)
ORIGINAL ARTICLES Index event biasda numerical example (2013) (0)
The long-term clinical course of acute deep vein thrombosis of the arm: a prospective cohort study (2003) (0)
Higher serum high-mobility group box 1 levels are cross-sectionally associated with micro- and macroalbuminuria, but not with cardiovascular disease in type 1 diabetes: the EURODIAB PCS (2011) (0)
No Difference in Risk of Recurrent Venous Thrombosis between Men and Women. Results from a Family Cohort Study in 3356 Subjects. (2007) (0)
LIFETIME FIBRE INTAKE AND ITS MAJOR DIETARY SOURCES ARE FAVOURABLY ASSOCIATED WITH ARTERIAL STIFFNESS IN YOUNG ADULTHOOD: THE AMSTERDAM GROWTH AND HEALTH LONGITUDINAL STUDY: PP.35.189 (2011) (0)
An algorithm for managing suspected pulmonary embolism - Reply (2006) (0)
LBA48ORAL RIVAROXABAN VERSUS STANDARD THERAPY FOR THE TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER (2014) (0)
Maastricht Utrecht Adherence in Hypertension Questionnaire (2013) (0)
Healthcare Cost Impact of Continued Anticoagulation with Rivaroxaban versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the EINSTEIN-CHOICE Trial Population Continued Anticoagulation with Rivaroxaban for Prevention of Recurrent Symptomatic Venous Thromboembolism in (2018) (0)
Risk for Venous Thromboembolism in Carriers of the Factor V Leiden Mutation (2003) (0)
The incidence of venous thromboembolism in asymptomatic carriers of the factor V leiden mutation: A prospective cohort study (1999) (0)
ICARVS-study : A prospective cohort study to assess the incidence of venous thromboembolism in asymptomatic carriers of the FV:Q(506) mutation. Preliminary results (1997) (0)
Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study (2012) (0)
Cholesteryl ester transfer protein (CETP) gene regulation: the effects of fibrates and statins on CETP mRNA and protein levels (2001) (0)
Other Uses of LMWHs – Miscellaneous (1998) (0)
Atherosclerosis as a potential risk factor of venous thrombosis (2003) (0)
thrombosis in thrombophilic families men is explained by sex-specific risk factors at time of first venous A lower risk of recurrent venous thrombosis in women compared with (2013) (0)
Clinical course of deep venous thrombosis [7] (multiple letters) (1997) (0)
AMUSE: Amsterdam Maastricht Utrecht study on Safety and cost-Effectiveness of a diagnostic decision rule for suspected deep venous thrombosis in general practice (2006) (0)
The Incidence of Subsegmental Pulmonary Emboli in Multi-Detector Row and Single-Detector Row CT (2007) (0)
The influence of genetic polymorphisms in the serotonin transporter on the effect of SSRI in depressive patients (2003) (0)
Oral contraceptives and cardiovascular disease (2002) (0)
Which is the outcome of the post-thrombotic syndrome? (1999) (0)
PEY5 THE COST-EFFECTIVENESS OF DIFFERENT CASE-FINDING STRATEGIES FOR DETECTION AND TREATMENT OF OCULAR HYPERTENSION AND PRIMARY OPEN-ANGLE GLAUCOMA BY THE OPHTHALMOLOGIST (2005) (0)
C0025: The Impact of Residual Thrombosis on the Outcome of Patients with Deep-Vein Thrombosis (2014) (0)
UvA-DARE ( Digital Academic Repository ) Atherosclerosis ; aspects of a multicultural disease (2007) (0)
On the True Prevalence of Pulmonary Embolism in Patients Hospitalized for a First Syncopal Event. (2019) (0)
Extended studies on the pathophysiology of dengue haemorrhagic fever; studies on haemostasis, immunology, virology and genetic markers aimed at developing intervention strategies (2000) (0)
Other Uses of LMWHs – Miscellaneous (1998) (0)
The incidence of venous thromboembolism in asymptomatic carriers of the factor V leiden mutation (1999) (0)
Below-knee stockings reduce post-thrombotic syndrome in patients with proximal deep vein thrombosis (2004) (0)
Optimale duur van secundaire preventie door orale toediening van vitamine K-antagonisten na diep veneuze trombose of longembolie (2000) (0)
Prevalence and Characteristics of Occult Cancer in Patients with Venous Thromboembolism. (2005) (0)
Risk Factors and Coagulation Disorders – LMWH Pharmacokinetics and Pharmacodynamics (1998) (0)
Abstract related to PL-22 Guidelines for antithrombotics in cancer patients (2012) (0)
Risk Factors and Coagulation Disorders – LMWH Pharmacokinetics and Pharmacodynamics (1998) (0)
Increased fetal loss in women with the factor V Leiden mutation. (1997) (0)
P-027 A male or female family history of VTE. Does it influence hormone-related VTE risk? (2013) (0)
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS The Incidence of Venous Thromboembolism in Asymptomatic Carriers of a Deficiency of Antithrombin, Protein C, or Protein S: A Prospective Cohort Study (2016) (0)
Performance Of The Simplified Pesi Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy (2013) (0)
UvA-DARE ( Digital Academic Repository ) Venous thromboembolism , coagulation and cancer (2009) (0)
Genetic susceptibility to pre-eclampsia : Involvement of factor V Leiden mutation (1997) (0)
AA Randomized Crossover Comparison between Oral Anti-coagulationn Self-Management and Management by the Thrombosiss Service in the Netherlands (2007) (0)
Does the presence of clinical symptoms of pulmonary embolism affect the outcome of patients with deep vein thrombosis? (2017) (0)
The EINSTEIN DVT Study: Does Localization of the Initial DVT Affect the Occurrence of Recurrent VTE While Patients Are on Anticoagulation? (2011) (0)
Residual Venous Thrombosis and Recurrent Thromboembolism (2003) (0)
Empirica ll evidenc e of design-relate d bias inn studie s of diagnosti c test s (2007) (0)
Peri-operative interruption of anticoagulant treatment in patients with atrial fibrillation and mechanical heart valves (the PIANO study) (2001) (0)
11 The Diagnosti c Odds Ratio : A singl e indicato r of tes t performanc e e (2007) (0)
Pulse pressure partially explains the increased incident cardiovascular disease associated with inflammation in type 1 diabetes: a 12-yr follow-up study (2010) (0)
PREGNANCY-RELATED THROMBOEMBOLISM. AUTHORS' REPLY (1997) (0)
Higher plasma sRAGE levels are associated with incident cardiovascular morbidity and mortality as well as all-cause mortality in type 1 diabetes: a 12-yr follow-up study (2009) (0)
Pregnancy-Related Thromboembolism (1997) (0)
International Good Clinical Practices Guidelines (GCPG) for Antithrombotics in CANCER Patients (2012) (0)
Endothelial dysfunction and inflammation partially explain the association between soluble RAGE and cardiovascular disease and albuminuria in type 1 diabetes: The EURODIAB Study (2008) (0)
Strategie ss for the evaluatio n of diagnosti cc technologie s (2007) (0)
[Treatment of intermittent claudication; prospective randomized study in the BAESIC-Trial (bypass, angioplasty or endarterectomy patients with severe intermittent claudication)]. (1996) (0)
Effectiveness of Management of Suspected Deep Vein Thrombosis in General Practice Based on a Clinical Decision Rule Including a Point of Care D-dimer Test. (2007) (0)
Comparing oral rivaroxaban versus standard care in the treatment of symptomatic deep vein thrombosis: a patient-reported satisfaction study (2012) (0)
Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutation: reply to a rebuttal (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Martin M.h. Prins?

Martin M.h. Prins is affiliated with the following schools: